MDXG vs MRK: fair value comparison
MiMedx Group, Inc. and Merck & Co., Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, MRK currently sits closer to the top of our discount ranking. MRK carries the stronger quality grade.
| MDXG | MRK | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $4.52 | $143.93 |
| 12-month range | $3.58–$7.52 | $82.49–$149.86 |
| Sector rank | #100 of 113 Healthcare | #95 of 113 Healthcare |
| Quality grade | D | C |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: MDXG fair value analysis · MRK fair value analysis